Dr. April Armstrong, MD
NPI: 1356477087
Total Payments
$2.7M
2024 Payments
$427,332
Companies
40
Transactions
1,816
Medicare Patients
346
Medicare Billing
$40,967
Payment Breakdown by Category
Consulting$1.5M (56.1%)
Other$809,187 (30.4%)
Research$166,358 (6.3%)
Travel$163,649 (6.2%)
Food & Beverage$27,055 (1.0%)
Education$1,939 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.5M | 464 | 56.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $790,467 | 273 | 29.7% |
| Unspecified | $166,358 | 142 | 6.3% |
| Travel and Lodging | $163,649 | 379 | 6.2% |
| Food and Beverage | $27,055 | 534 | 1.0% |
| Honoraria | $10,970 | 4 | 0.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,350 | 2 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,400 | 1 | 0.1% |
| Education | $1,939 | 16 | 0.1% |
| Grant | $1,000 | 1 | 0.0% |
Payments by Type
General
$2.5M
1,674 transactions
Research
$166,358
142 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $376,550 | 309 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $270,291 | 133 | $0 (2024) |
| Lilly USA, LLC | $268,847 | 186 | $0 (2024) |
| GENZYME CORPORATION | $234,622 | 115 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $183,545 | 125 | $0 (2024) |
| Eli Lilly and Company | $163,504 | 88 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $157,590 | 126 | $0 (2024) |
| UCB, Inc. | $143,237 | 90 | $0 (2024) |
| Janssen Biotech, Inc. | $108,045 | 106 | $0 (2024) |
| LEO Pharma Inc. | $103,638 | 59 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $427,332 | 251 | E.R. Squibb & Sons, L.L.C. ($69,722) |
| 2023 | $380,558 | 254 | E.R. Squibb & Sons, L.L.C. ($58,329) |
| 2022 | $354,241 | 235 | E.R. Squibb & Sons, L.L.C. ($94,219) |
| 2021 | $336,775 | 159 | AbbVie Inc. ($57,384) |
| 2020 | $224,958 | 108 | AbbVie Inc. ($39,686) |
| 2019 | $207,936 | 197 | Novartis Pharmaceuticals Corporation ($30,636) |
| 2018 | $228,305 | 207 | Lilly USA, LLC ($86,939) |
| 2017 | $500,831 | 405 | Lilly USA, LLC ($96,618) |
All Payment Transactions
1,816 individual payment records from CMS Open Payments — Page 1 of 73
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/28/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $6,915.81 | General |
| 12/28/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $187.00 | General |
| 12/27/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,887.00 | General |
| 12/19/2024 | Lilly USA, LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $15,300.00 | General |
| 12/19/2024 | Lilly USA, LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| 12/19/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $578.71 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $487.00 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $194.69 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $171.76 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $159.50 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $139.64 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $110.16 | General |
| 12/18/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $69.55 | General |
| 12/16/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $15.87 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| 12/13/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $882.95 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $262.20 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $238.41 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $171.46 | General |
| 12/11/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $292.03 | General |
| 12/11/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $237.54 | General |
| 12/11/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $209.45 | General |
| 12/11/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $173.34 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $22,910 | 23 |
| A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis (AD) | Kyowa Kirin Pharmaceutical Development, Inc | $19,369 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $14,858 | 16 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $12,900 | 2 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $11,600 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $6,562 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAI | UCB, Inc. | $6,180 | 1 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $4,709 | 5 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,075 | 8 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY | UCB, Inc. | $3,940 | 5 |
| Ph4 Otezla in oligoarticular PsA FOREMOST/KEG | Amgen Inc. | $3,629 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $3,468 | 3 |
| Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis | UCB, Inc. | $2,800 | 1 |
| Early initiation of Apremilast. | Amgen Inc. | $2,611 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,564 | 4 |
| Real-World Effectiveness of Initiating Topical Therapy Compared With Initiating Apremilast | Amgen Inc. | $2,548 | 1 |
| A RETROSPECTIVE COHORT STUDY OF THE INCIDENCE OF PSORIATIC ARTHRITIS IN ADULT PATIENTS WITH MILD, MODERATE OR SEVERE PSORIASIS USING A US ELECTRONIC HEALTH RECORDS DATABASE | Novartis Pharmaceuticals Corporation | $2,500 | 1 |
| CHARACTERISTICS, TREATMENT PATTERNS, AND TREATMENT SATISFACTION AMONG PSORIASIS PATIENTS TREATED WITH COSENTYX (SECUKINUMAB) | Novartis Pharmaceuticals Corporation | $2,500 | 1 |
| TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB | LEO Pharma AS | $2,490 | 1 |
| A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety of bimekizumab in adult subjects with moderate to | UCB, Inc. | $2,300 | 1 |
| A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17 | UCB, Inc. | $2,300 | 1 |
| Long-term efficacy and safety of bimekizumab and other biologics in moderate to severe plaque psoriasis- Updated systematic literature review and network meta-analysis | UCB, Inc. | $2,300 | 1 |
| Real-World Study Evaluating AdeQUacy of Existing Systemic Treatments for Patients with Moderate-to-Severe Atopic Dermatitis (AD-QUEST): Baseline Treatment Patterns and Unmet Needs Assessment | SANOFI-AVENTIS U.S. LLC | $2,116 | 6 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS W | UCB, Inc. | $2,060 | 5 |
| RW pattern and consequence of inappropriate use of systemic steroid (STATinMED) manuscript | SANOFI-AVENTIS U.S. LLC | $1,680 | 1 |
| Publication support research related | Novartis Pharma AG | $1,567 | 1 |
| RW pattern and consequence of immunosuppressants use (STATinMED) manuscript | SANOFI-AVENTIS U.S. LLC | $1,518 | 1 |
| TRUVEN | SANOFI-AVENTIS U.S. LLC | $1,402 | 7 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $1,336 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,285 | 2 |
| RW consequence of conventional systemic treatment of payer claim database (Humana) | SANOFI-AVENTIS U.S. LLC | $1,158 | 1 |
| Real-World Consequences of Conventional Systemic Treatment from a Payer Claim Database | SANOFI-AVENTIS U.S. LLC | $1,096 | 1 |
| Truven/StatinMed | SANOFI-AVENTIS U.S. LLC | $1,034 | 2 |
| Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis | SANOFI-AVENTIS U.S. LLC | $974.03 | 2 |
| ADELPHI | SANOFI-AVENTIS U.S. LLC | $898.45 | 4 |
| AD-1334: Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1); AD-1416: Study of Dupilumab (REGN668/SAR231893) Monothera | SANOFI-AVENTIS U.S. LLC | $875.79 | 2 |
| A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety | UCB, Inc. | $820.00 | 1 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $720.00 | 1 |
| STATinMED | SANOFI-AVENTIS U.S. LLC | $537.82 | 2 |
| Real-World Utilization Patterns of Systemic Immunosuppressants Among US Adult Patients with Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $517.62 | 1 |
| Treatment-emergent acute complications (TEACs) from Immunosuppressant Use in Adult Patients with Atopic Dermatitis in the US | SANOFI-AVENTIS U.S. LLC | $517.17 | 2 |
| The economic burden associated with time to therapy escalation for patients with atopic dermatitis uncontrolled with topical therapies | SANOFI-AVENTIS U.S. LLC | $454.29 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIA | UCB, Inc. | $420.00 | 1 |
| Comparative effectiveness of bimekizumab for the treatment of plaque psoriasis: a network meta-analysis | UCB, Inc. | $420.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJ | UCB, Inc. | $400.00 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFIC | UCB, Inc. | $400.00 | 1 |
| Comparative Efficacy of Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis | UCB, Inc. | $400.00 | 1 |
| AG/Truven | SANOFI-AVENTIS U.S. LLC | $344.44 | 1 |
| Economic Outcomes Associated with Unsuitable Immunosuppressant Use in Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $322.07 | 1 |
| Real-world Effectiveness of Dupilumab in Atopic Dermatitis (AD): Improvement in AD Signs as Assessed by the Investigator Global Assessment (IGA) in an Electronic Medical Records Dataset | SANOFI-AVENTIS U.S. LLC | $289.09 | 1 |
| Physician experiences and perceptions of systemic therapies for atopic dermatitis in the United States | SANOFI-AVENTIS U.S. LLC | $266.67 | 1 |
| AN EXPLORATORY RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EXPLORE THE MODULATION OF INFLAMMATION IN THE SKIN CUTANEOUS ADIPOSE TISSUE AND BLOOD ENDOTHELIAL CELL INTERFACE BY COSENTYX SECUKINUMAB VERSUS PLACEBO IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS ADIPSO | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
| Outcomes of unsuitable IMMs use (Truven) AMCP abstract | SANOFI-AVENTIS U.S. LLC | $229.71 | 1 |
| A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $224.40 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $156.55 | 1 |
| TCS/TCI initiator analysis (STATinMED) SID abstract | SANOFI-AVENTIS U.S. LLC | $153.91 | 1 |
| Modernizing Medicine: IGA & NRS | SANOFI-AVENTIS U.S. LLC | $152.19 | 1 |
| Economic outcomes associated with unsuitable immunosuppressant use in moderate-to-severe atopic dermatitis | SANOFI-AVENTIS U.S. LLC | $113.15 | 1 |
| AG/TRUVEN | SANOFI-AVENTIS U.S. LLC | $91.50 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $34.43 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 142 | 236 | $98,329 | $13,998 |
| 2022 | 4 | 95 | 126 | $47,860 | $12,156 |
| 2021 | 3 | 67 | 88 | $37,320 | $9,600 |
| 2020 | 2 | 42 | 57 | $25,000 | $5,213 |
Total Patients
346
Total Services
507
Medicare Billing
$40,967
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 76 | $43,682 | $7,781 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 29 | $24,882 | $2,402 | 9.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 13 | $11,680 | $1,816 | 15.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 19 | 21 | $8,197 | $976.20 | 11.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 13 | 14 | $6,398 | $538.03 | 8.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 14 | 83 | $3,490 | $485.38 | 13.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 48 | 76 | $30,400 | $7,542 | 24.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $9,600 | $2,106 | 21.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 19 | 20 | $5,200 | $1,928 | 37.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 12 | 14 | $2,660 | $581.22 | 21.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 37 | 57 | $22,800 | $5,640 | 24.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $11,400 | $2,679 | 23.5% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 11 | 12 | $3,120 | $1,281 | 41.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 31 | 46 | $18,400 | $4,185 | 22.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $6,600 | $1,029 | 15.6% |
About Dr. April Armstrong, MD
Dr. April Armstrong, MD is a Clinical & Laboratory Dermatological Immunology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356477087.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. April Armstrong, MD has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $427,332 received in 2024. These payments were reported across 1,816 transactions from 40 companies. The most common payment nature is "Consulting Fee" ($1.5M).
As a Medicare-enrolled provider, Armstrong has provided services to 346 Medicare beneficiaries, totaling 507 services with total Medicare billing of $40,967. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical & Laboratory Dermatological Immunology
- Other Specialties Pediatric Dermatology, Dermatology
- Location Los Angeles, CA
- Active Since 02/26/2007
- Last Updated 07/12/2023
- Taxonomy Code 207NI0002X
- Entity Type Individual
- NPI Number 1356477087
Products in Payments
- TALTZ (Drug) $258,342
- TREMFYA (Drug) $168,730
- COSENTYX (Biological) $128,710
- DUPIXENT (Biological) $124,570
- Sotyktu (Drug) $116,433
- SKYRIZI (Biological) $115,258
- DUPIXENT (Drug) $84,933
- DUPIXENT DUPILUMAB INJECTION (Biological) $79,020
- Humira (Biological) $75,023
- Bimzelx (Biological) $64,030
- STELARA (Biological) $59,304
- ATOPIC DERMATITIS - DISEASE (Drug) $50,734
- RINVOQ (Biological) $44,276
- Tremfya (Drug) $33,348
- ADBRY (Biological) $28,532
- VTAMA (Drug) $27,383
- ENSTILAR (Drug) $23,196
- AIN457A_COSENTYX_DERMATOLOGY (Biological) $19,390
- CIBINQO (Drug) $17,170
- Otezla (Drug) $15,756
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.